1.00 / AMA PRA Category 1 CreditTM 1.00 / CNE Contact Hour
Sponsored by Academy for Continued Healthcare Learning
Supported by an educational grant from Portola Pharmaceuticals, Inc.
Dr. Gregory Piazza and Dr. Christian Ruff present recent clinical data, guideline recommendations and updates on navigating the use of newly approved and emerging NOAC reversal agents. This video commentary will include clinical case review and discussions about strategies to navigate the complexities of reversing the anticoagulant effects of NOACs across diverse patient populations in emergent medical situations.
This activity is intended for hospitalists, cardiologists, primary care physicians, Nurses, and others with an interest in NOAC reversal.
Upon proper completion of this activity, participants should be better able to:
Review current approaches to the management of bleeding in patients receiving NOACs, as well as unmet needs with current practices
Compare and contrast approved and emerging reversal agents for NOACs, including their mechanisms of action and available data
Discuss clinical strategies for NOAC reversal in emergent patient scenarios
Conflict of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Christian Ruff, MD, MPH Assistant Professor of Medicine, Harvard Medical School Associate Physician and Investigator – TIMI Study Group Cardiovascular Division, Brigham and Women’s Hosptial Boston, MA
Dr. Ruff discloses the following: Sources of Funding for Research: Boehringer Ingelheim, Daiichi Sankyo, MedImmune, National Institutes of Health Consulting Agreements/Advisory Boards: Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola, Anthos
Gregory Piazza, MD, MS Associate Physician, Brigham and Women’s Hospital Associate Professor, Harvard Medical School Boston, MA
Dr. Piazza discloses the following: Grants: Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Portola Pharmaceuticals, Inc. Advisory Panel: Pfizer
Accredited Provider Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
Provider approved by the California Board of Registered Nursing, Provider Number 17273.
This activity is approved for 1.00 contact hour.
Disclosure of Unlabeled Use
Discussion of Investigational Drug Use: ciraparantag agent for the reversal of the anticoagulant effect in patients treated with novel oral anticoagulants (NOACs) or low molecular weight heparin
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 1 hour to complete. To receive credit, participants are required to complete the pre-test, view the online activity and complete the post-test and evaluation. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available and emailed, please be sure to check spam/junk mailbox. There is no fee to participate in the activity or for the generation of the certificate.
Your certificate will be saved on the ACHL website and will not be available in your myCME History.